WealthPLAN Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

WealthPLAN Partners’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15	Closed	-$10.4K	–	348
2023 Q3	$10.4K	Buy	15 +2	+15%	+$8.57K	﹤0.01%	314
2023 Q2	$60.3K	Sell	13 -6	-32%	-$20.8K	0.01%	480
2023 Q1	$50.9K	Sell	19 -1	-5%	-$2.93K	0.01%	551
2022 Q4	$55.1K	Buy	+20	New	+$69.7K	﹤0.01%	387
2022 Q1	$33K	Hold	14	–	–	﹤0.01%	379
2021 Q4	$60K	Buy	14 +2	+17%	+$15.4K	﹤0.01%	375
2021 Q3	$84K	Buy	12 +3	+33%	+$25.8K	0.01%	370
2021 Q2	$78K	Buy	9 +4	+80%	+$65.7K	0.01%	353
2021 Q1	$117K	Hold	5	–	–	0.01%	328
2020 Q4	$57K	Hold	5	–	–	﹤0.01%	330
2020 Q3	$18K	Hold	5	–	–	﹤0.01%	312
2020 Q2	$21K	Hold	5	–	–	﹤0.01%	307
2020 Q1	$15K	Hold	5	–	–	﹤0.01%	252
2019 Q4	$16K	Hold	5	–	–	﹤0.01%	246
2019 Q3	$14K	Buy	5 +2	+67%	+$12.1K	﹤0.01%	233
2019 Q2	$17K	Buy	+3	New	+$31.6K	﹤0.01%	238

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

WealthPLAN Partners's SEEL Position: Q4 2023 in Review

WealthPLAN Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 15 shares — an estimated $10.4K sold.

WealthPLAN Partners first reported a position in SEEL in Q2 2019 and held it in 16 quarters. The position peaked at $117K in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

WealthPLAN Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
WealthPLAN Partners sold 15 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $10.4K.
WealthPLAN Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
WealthPLAN Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $117K in Q1 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on WealthPLAN Partners's 13F filing for Q4 2023, filed 5 Jan 2024.